D0039 | Didanosine

Molecular Formula C10H12N4O3
Molecular Weight 236.23
State solid
Route of elimination Based on data from in vitro and animal studies, it is presumed that the metabolism of didanosine in man occurs by the same pathways responsible for the elimination of endogenous purines. Purines are eliminated by the kidneys.
Protein binding Low (<5%)
Half life 30 minutes in plasma and more than 12 hours in intracellular environment.
Absorption Rapidly absorbed (bioavailability 30-40%) with peak plasma concentrations appearing within 0.5 and 1.5 hrs.
Trade names Videx
Description dideoxynucleoside; nucleoside analogue of adenosine; inhibitor of HIV replication; reverse-transcriptase inhibitor


J05AF02 Didanosine

[J05AF] Nucleoside and nucleotide reverse transcriptase inhibitors



[J] Antiinfectives for systemic use

Toxicity Dose Time Species Model Method Action Positive criterion Reference

Target Dose Time Species Model Method Action Positive criterion Reference
DNA polymerase gamma 194

Pictogram Signal Statements Precautionary Statement Codes

Aggregated GHS information provided by 4 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

H315 (25%): Causes skin irritation [Warning Skin corrosion/irritation]

H319 (25%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

H335 (25%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure

Respiratory tract irritation]

H341 (75%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]

H372 (25%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

P201, P202, P260, P261, P264, P270, P271, P280, P281, P302+P352, P304+P340, P305+P351+P338, P308+P313, P312, P314, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

  • Disease progression

  • Immunodeficiency

  • Infection

  • Liver disorder

  • Pancreatitis

  • Renal failure

  • Renal impairment

  • Abdominal pain

  • Dermatitis

  • Diarrhoea

  • Gastrointestinal pain

  • Neurological symptom

  • Neuropathy peripheral

  • Pancreatitis

  • Pruritus

  • Rash

  • Didanosine;

    DrugBank Name Didanosine
    DrugBank DB00900
    CAS Number 69655-05-6
    PubChem Compound 135398739
    KEGG Compound ID C06953
    KEGG Drug D00296
    PubChem.Substance 46506255
    ChEBI 490877
    PharmGKB PA449301
    ChemSpider 45864
    BindingDB 50404252.0
    TTD DNC000528
    Wikipedia Didanosine
    HET 2DI
    DPD 916

    1. Dykens et al. (2007)
    2. Chan et al. (2005)